209 related articles for article (PubMed ID: 14981579)
41. Proteasome inhibition with bortezomib enhances activity of topoisomerase I-targeting drugs by NF-kappaB-independent mechanisms.
Takigawa N; Vaziri SA; Grabowski DR; Chikamori K; Rybicki LR; Bukowski RM; Ganapathi MK; Ganapathi R; Mekhail T
Anticancer Res; 2006; 26(3A):1869-76. PubMed ID: 16827119
[TBL] [Abstract][Full Text] [Related]
42. Proteasome inhibition in small-cell lung cancer: preclinical rationale and clinical applications.
Lara PN; Bold RJ; Mack PC; Davies AM; Gumerlock PH; Gandara DR
Clin Lung Cancer; 2005 Oct; 7 Suppl 2():S67-71. PubMed ID: 16250931
[TBL] [Abstract][Full Text] [Related]
43. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma.
Gordon GJ; Mani M; Maulik G; Mukhopadhyay L; Yeap BY; Kindler HL; Salgia R; Sugarbaker DJ; Bueno R
Cancer Chemother Pharmacol; 2008 Apr; 61(4):549-58. PubMed ID: 17522864
[TBL] [Abstract][Full Text] [Related]
44. Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors.
Neri P; Ren L; Gratton K; Stebner E; Johnson J; Klimowicz A; Duggan P; Tassone P; Mansoor A; Stewart DA; Lonial S; Boise LH; Bahlis NJ
Blood; 2011 Dec; 118(24):6368-79. PubMed ID: 21917757
[TBL] [Abstract][Full Text] [Related]
45. Proteasome inhibition as a novel therapeutic target in human cancer.
Rajkumar SV; Richardson PG; Hideshima T; Anderson KC
J Clin Oncol; 2005 Jan; 23(3):630-9. PubMed ID: 15659509
[TBL] [Abstract][Full Text] [Related]
46. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.
Nawrocki ST; Carew JS; Pino MS; Highshaw RA; Andtbacka RH; Dunner K; Pal A; Bornmann WG; Chiao PJ; Huang P; Xiong H; Abbruzzese JL; McConkey DJ
Cancer Res; 2006 Apr; 66(7):3773-81. PubMed ID: 16585204
[TBL] [Abstract][Full Text] [Related]
47. Proteasome: an emerging target for cancer therapy.
Zavrski I; Jakob C; Schmid P; Krebbel H; Kaiser M; Fleissner C; Rosche M; Possinger K; Sezer O
Anticancer Drugs; 2005 Jun; 16(5):475-81. PubMed ID: 15846112
[TBL] [Abstract][Full Text] [Related]
48. Discovery, Development, and clinical applications of bortezomib.
Jung L; Holle L; Dalton WS
Oncology (Williston Park); 2004 Dec; 18(14 Suppl 11):4-13. PubMed ID: 15688597
[TBL] [Abstract][Full Text] [Related]
49. TNF potentiates anticancer activity of bortezomib (Velcade) through reduced expression of proteasome subunits and dysregulation of unfolded protein response.
Nowis D; McConnell EJ; Dierlam L; Palamarchuk A; Lass A; Wójcik C
Int J Cancer; 2007 Jul; 121(2):431-41. PubMed ID: 17373661
[TBL] [Abstract][Full Text] [Related]
50. [A new therapy with bortezomib, an oncologic medicinal product of the year 2004].
Monneret C; Buisson JP; Magdelenat H
Ann Pharm Fr; 2005 Sep; 63(5):343-9. PubMed ID: 16385784
[TBL] [Abstract][Full Text] [Related]
51. The proteasome as a potential target for novel anticancer drugs and chemosensitizers.
Landis-Piwowar KR; Milacic V; Chen D; Yang H; Zhao Y; Chan TH; Yan B; Dou QP
Drug Resist Updat; 2006 Dec; 9(6):263-73. PubMed ID: 17197231
[TBL] [Abstract][Full Text] [Related]
52. The proteasome: a worthwhile target for the treatment of solid tumours?
Milano A; Iaffaioli RV; Caponigro F
Eur J Cancer; 2007 May; 43(7):1125-33. PubMed ID: 17379504
[TBL] [Abstract][Full Text] [Related]
53. [Promising targeted molecular therapies for the future years in non-small-cell lung cancer].
Soria JC
Rev Pneumol Clin; 2006 Feb; 62 Spec no 1():1S35-6. PubMed ID: 16719155
[No Abstract] [Full Text] [Related]
54. Proteasome inhibitors in the clinical setting: benefits and strategies to overcome multiple myeloma resistance to proteasome inhibitors.
Cheriyath V; Jacobs BS; Hussein MA
Drugs R D; 2007; 8(1):1-12. PubMed ID: 17249845
[TBL] [Abstract][Full Text] [Related]
55. The emerging role of bortezomib in the treatment of indolent non-Hodgkin's and mantle cell lymphomas.
O'Connor OA
Curr Treat Options Oncol; 2004 Aug; 5(4):269-81. PubMed ID: 15233904
[TBL] [Abstract][Full Text] [Related]
56. Bortezomib as an antitumor agent.
Roccaro AM; Hideshima T; Richardson PG; Russo D; Ribatti D; Vacca A; Dammacco F; Anderson KC
Curr Pharm Biotechnol; 2006 Dec; 7(6):441-8. PubMed ID: 17168660
[TBL] [Abstract][Full Text] [Related]
57. Bortezomib as a potential treatment for prostate cancer.
Papandreou CN; Logothetis CJ
Cancer Res; 2004 Aug; 64(15):5036-43. PubMed ID: 15289299
[TBL] [Abstract][Full Text] [Related]
58. Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro.
Mitsiades CS; McMillin D; Kotoula V; Poulaki V; McMullan C; Negri J; Fanourakis G; Tseleni-Balafouta S; Ain KB; Mitsiades N
J Clin Endocrinol Metab; 2006 Oct; 91(10):4013-21. PubMed ID: 16849420
[TBL] [Abstract][Full Text] [Related]
59. Anti-tumor activity of the proteasome inhibitor bortezomib in gastric cancer.
Nakata W; Hayakawa Y; Nakagawa H; Sakamoto K; Kinoshita H; Takahashi R; Hirata Y; Maeda S; Koike K
Int J Oncol; 2011 Dec; 39(6):1529-36. PubMed ID: 21785822
[TBL] [Abstract][Full Text] [Related]
60. Clinical update: proteasome inhibitors in solid tumors.
Lenz HJ
Cancer Treat Rev; 2003 May; 29 Suppl 1():41-8. PubMed ID: 12738242
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
